This will be a single site safety and proof of concept study conducted at the Indiana
University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective
disorders will be randomized 1:1 to double-blind treatment with fingolimod or matched placebo
for duration of 8 weeks.